Global Pediatric Neuroblastoma Treatment Market Report 2023: Forecast Market Size, Growth Rate And Key Drivers
6 Jun, 2023
The global pediatric neuroblastoma treatment market size is expected to grow from $1.52 billion in 2022 to $1.67 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pediatric neuroblastoma treatment market size is expected to reach $2.37 billion in 2027 at a CAGR of 9.1%.
Global Pediatric Neuroblastoma Treatment Market Key Driver
The rising number of new cases of paediatric neuroblastoma is likely to boost the paediatric neuroblastoma therapy market forward in the coming years. The increasing prevalence of neuroblastoma raises the demand for paediatric neuroblastoma treatment options. As a result, pharmaceutical businesses and other stakeholders have increased their investment in R&D, promoting industry innovation. Furthermore, the availability of modern diagnostic equipment and screening protocols has resulted in the earlier detection of neuroblastoma, allowing for earlier treatment and better outcomes.
Get a sample of the global pediatric neuroblastoma treatment market reportGlobal Pediatric Neuroblastoma Treatment Market Segments
The global pediatric neuroblastoma treatment market is segmented:
1) By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatment Types
2) By Risk Group: Low Risk, Intermediate Risk, High Risk
3) By End User: Hospitals, Specialty Clinics, Other End Users
4) By Geography: The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global pediatric neuroblastoma treatment market.
Major Pediatric Neuroblastoma Treatment Industry Players
United Therapeutics Corporation, APEIRON Biologics AG, Baxter International Inc., Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Sartorius AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, CureSearch for Children's Cancer
Get the full global pediatric neuroblastoma treatment market reportPediatric Neuroblastoma Treatment Market Overview
Pediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. Neuroblastoma is typically treated with a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
Pediatric Neuroblastoma Treatment Global Market Report 2023 provides data on the global pediatric neuroblastoma treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The pediatric neuroblastoma treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.